Mats Wahlstrom - 25 Feb 2022 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Director
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Mats Wahlstrom
Issuer symbol
CHRS
Transactions as of
25 Feb 2022
Net transactions value
+$178,934
Form type
4
Filing time
01 Mar 2022, 19:22:07 UTC
Previous filing
11 Feb 2022
Next filing
09 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Award $116,433 +10,006 $11.64 10,006 25 Feb 2022 Direct
transaction CHRS Common Stock Award $62,501 +29,994 +300% $2.08 40,000 28 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Options Exercise $0 +29,994 $0.000000* 0 28 Feb 2022 Common Stock 29,994 $2.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option are fully vested and exercisable.